Search results
Results from the WOW.Com Content Network
Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars. [1] They are a bio-marker implicated in aging and the development, or worsening, of many degenerative diseases , such as diabetes , atherosclerosis , chronic kidney disease , and Alzheimer's disease .
Sorbitol may also glycate nitrogens on proteins, such as collagen, and the products of these glycations are referred-to as AGEs - advanced glycation end-products. AGEs are thought to cause disease in the human body, one effect of which is mediated by RAGE (receptor for advanced glycation end-products) and the ensuing inflammatory responses induced.
An important way AGEs exert their effect is through a receptor-mediated mechanism, most importantly by the receptor for advanced glycation end products (RAGE). RAGE is a signal transduction receptor found on a number of cell types including macrophages, endothelial cells, renal mesangial cells and podocytes in the glomerulus. [ 26 ]
Download as PDF; Printable version; In other projects Wikidata item; ... Help. Pages in category "Advanced glycation end-products" The following 8 pages are in this ...
Schematic of the relation between an immunoglobulin and RAGE Schematic of the RAGE gene and its products. RAGE (receptor for advanced glycation endproducts), also called AGER, is a 35 kilodalton transmembrane receptor [5] of the immunoglobulin super family which was first characterized in 1992 by Neeper et al. [6] Its name comes from its ability to bind advanced glycation endproducts (), which ...
N(6)-Carboxymethyllysine (CML), also known as N ε-(carboxymethyl)lysine, is an advanced glycation endproduct (AGE). CML has been the most used marker for AGEs in food analysis. CML has been the most used marker for AGEs in food analysis.
Pimagedine was under development as a drug for kidney diseases by the pharmaceutical company Alteon (now known Synvista Therapeutics Inc.) that was founded in 1986. [2] In 1987, Alteon acquired a license to intellectual property relating to AGE inhibition from Rockefeller University. [3]
Sevelamer is able to sequester advanced glycation end products (AGEs) in the gut, preventing their absorption into the blood. AGEs contribute to oxidative stress, which can damage cells (like beta cells, which produce insulin in the pancreas).